Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,704.00
(
-0.39%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.49
(
3.66%
)
Bitcoin
70,532.60
(
-1.00%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Mpower

Send PM Follow Ignore
Followers 2
Posts 635
Boards Moderated 0
Alias Born 04/23/2007

Mpower

Re: jmkobers post# 100849

Thursday, 08/05/2010 12:57:03 PM

Thursday, August 05, 2010 12:57:03 PM

Post# of 257257
In the event of a non-substitutable approval for TEVA, MNTA sole-generic royalty structure would remain in-tact.

Sanofi AG decision would depend on what Sanofi wants to do ... i suspect they would refrain from a AG in such a scenario.

Please refer to Dew's Readmefirst for more detailed discussion around the aforementioned scenario.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now